Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00236145
Status:
COMPLETED
Last Update Posted:
2013-01-29
First Post:
2005-10-07
Brief Title:
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
Sponsor:
Cephalon
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Randomised Open-label Parallel-group Study to Evaluate the Efficacy and Safety of ACTIQ Oral Transmucosal Fentanyl Citrate Titrated According to 2 Regimens in Patients With Cancer and Breakthrough Pain
Status:
COMPLETED
Status Verified Date:
2005-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to determine whether a test titration regimen of ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain for an individual patient by attaining a successful dose of ACTIQ treatment more quickly The successful ACTIQ dose provides a satisfactory combination of efficacy and tolerability after a single administration as assessed by the patient
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None